Trial reportSchizophrenia research2011
The association between weight change and symptom reduction in the CATIE schizophrenia trial.
Trial report in Schizophrenia research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.The lancet. Psychiatry · 2020Pooled it
- Perphenazine for schizophrenia.The Cochrane database of systematic reviews · 2015Pooled it
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.Schizophrenia research · 2014Trial
- Trial
- Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology · 2013Trial
- Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry · 2013Trial
- Clozapine-associated Weight Loss: A Case Series.Indian journal of psychological medicine · 2025Article
- Association between Empathy and Clinical Symptoms among Overweight and Non-Overweight Chinese Chronic Schizophrenia Patients.Brain sciences · 2023Article
- Intrinsic Therapeutic Link between Recuperative Cerebellar Con-Nectivity and Psychiatry Symptom in Schizophrenia Patients with Comorbidity of Metabolic Syndrome.Life (Basel, Switzerland) · 2023Article
- Oral and long-acting injectable antipsychotic discontinuation and relationship to side effects in people with first episode psychosis: a longitudinal analysis of electronic health record data.Therapeutic advances in psychopharmacology · 2023Article
- Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study.Frontiers in pharmacology · 2023Article
- Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behavioral sciences (Basel, Switzerland) · 2021Review
- Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.Behavioural brain research · 2021Review
- Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Do Leptin Play a Role in Metabolism-Related Psychopathological Symptoms?Frontiers in psychiatry · 2021Article
- Homocysteine level, body mass index and clinical correlates in Chinese Han patients with schizophrenia.Scientific reports · 2020Article
- Baseline brain structural and functional predictors of clinical outcome in the early course of schizophrenia.Molecular psychiatry · 2020Article
- Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia.Translational psychiatry · 2020Article
- Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis.Clinical proteomics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundWeight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit.
methodsData from the CATIE schizophrenia trial comparing the effectiveness of perphenazine, olanzapine, risperidone, quetiapine and ziprasidone in a randomized, double-blind, trial over 18 months were used to evaluate the relationship between percent change in body mass index (BMI) and change in total serum cholesterol and triglycerides with the Positive and Negative Syndrome Scale (PANSS) score. Analysis of covariance for observations at 3 months and a mixed effects model for all observations up to 18 months adjusted for potentially confounding variables were used to examine these associations.
resultsIn both models, there was a significant association (p = 0.001) between change in PANSS total score and percent change in BMI, equating to a 0.28 and 0.21 point decrease in PANSS total score (range 30-210) per 1% increase in BMI respectively. Change in BMI accounted for 3% or less of variance for change in PANSS scores. There was no evidence that the association of symptoms and weight gain differed across medications in spite of substantial differences in weight gain and other metabolic measures. Neither total serum cholesterol nor triglyceride levels displayed a significant association with change in PANSS.
conclusionThe magnitude of the relationship between change in BMI and PANSS was too small to be clinically important, indicating that switching medications to one with less metabolic risk is unlikely to result in meaningful loss of clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.